76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Nektar Therapeutics
Open
0.66 -2.94
Overview
Share price change
24h
Min
0.65
Max
0.68
Income | -58M -51M |
|---|---|
Sales | -19M 10M |
EPS | -0.24 |
Profit margin | -486.444 |
Employees | 61 |
EBITDA | -58M -41M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +580% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | 15M 148M |
|---|---|
Previous open | 3.6 |
Previous close | 0.66 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Nektar Therapeutics Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Nektar Therapeutics Forecast
Price Target
By TipRanks
580% upside
12 Months Forecast
Average 5.1 USD 580%
High 7 USD
Low 2 USD
Based on 6 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
